Tafluprost, a new potent prostanoid receptor agonist: A dose-response study on pharmacodynamics and tolerability in healthy volunteers

Sutton A., Gouws P., Ropo A.

2008
International Journal of Clinical Pharmacology and Therapeutics

View publication

Therapeutic Area

Glaucoma
Categories

Clinical development

Affiliations

Guildford Clinical Pharmacology Ltd., Technology Center, Guildford, Surrey, United Kingdom; Conquest Hospital, Ridge, St. Leonards-on-Sea, East Sussex, United Kingdom; Santen Oy Clinical Research, Tampere, Finland; Cedars Vanzell Road, Midhurst, West Sussex GU29 9BA, United Kingdom

Related Publications

Long-term safety and efficacy of sepetaprost, with or without timolol, in patients with open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J2 study

Inatani M., Tone Y., Ikeda T., Angeles R.

Efficacy and safety of sepetaprost in patients with primary open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J1 study

Inatani M., Kanamori A., Inai M., Ikeda T., Angeles R.

Clinical outcomes of Preserflo MicroShunt implant procedure in open‑angle glaucoma patients – a 1000 eyes case-series; including subanalysis of combined cataract-glaucoma surgery and standalone surgery in pseudophakic eyes

Klabe, K.; Werth, J.P.; Kaymak, H. ; Fricke, A.

View all Glaucoma publications

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022